ArticleTranslational vision science & technology2026
OptiDON-Guard: An Ensemble Model for Identification of Dysthyroid Optic Neuropathy Using Optical Coherence Tomography Angiography.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the value of machine learning models based on optical coherence tomography angiography (OCTA) in identifying dysthyroid optic neuropathy (DON). Methods: A retrospective, dual-center, cross-sectional study was conducted involving 346 thyroid eye disease patients (with/without DON) from two institutions. Participants underwent ophthalmic examinations, including OCTA scans centered on the macula and optic nerve head. The OCTA data from Center 1 were split into a training set and an internal validation set, while the data from Center 2 served as an external test set. Features were extracted from OCTA images, and a wrapper-based feature selection strategy identified the optimal subset. A two-tiered stacking modeling framework was used, incorporating baseline model construction, data augmentation using pseudo-labeling, and ensemble integration. Model performance (area under the curve [AUC], accuracy, sensitivity, specificity, precision) was evaluated alongside receiver operating characteristic, calibration, and decision curve analyses. Additionally, the SHapley Additive exPlanation method was used to interpret feature contributions. Results: The ensemble model, OptiDON-Guard, demonstrated superior performance to individual models on both internal validation and external test sets. In the internal validation set, it achieved an AUC of 0.872, accuracy of 0.943, sensitivity of 0.667, specificity of 0.979, and precision of 0.943. In the external test set, it maintained strong performance with an AUC of 0.854, accuracy of 0.816, sensitivity of 0.767, specificity of 0.842, and precision of 0.854. Conclusions: The OptiDON-Guard is a reliable, interpretable, and clinically applicable tool for identifying DON. Translational Relevance: The OptiDON-Guard offers a valuable clinical tool to enhance the diagnostic precision of DON.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.